The Experts below are selected from a list of 15 Experts worldwide ranked by ideXlab platform
Yao Jian-hua - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Avascular Necrosis of Femoral Head by Implanting a Composite of Bone Marrow,Bone Morphogenetic Protein,and Noncelluar Tissue Engineered Bone Allograft
China Medical Device Information, 2007Co-Authors: Yao Jian-huaAbstract:Objective: To investigate the effect of treatment of avascular necrosis of femoral head in adolescence by implanting a composite of red Bone marrow, Bone morphogenetic protein, and noncelluar tissue Engineered Bone Allograft. Method: The Bone Allograft chips (sponge Bone) and Allograft fibula segments were partial dematerialized and then freeze-dried, steriled by radiation. The Bone morphogenetic protein was partial purified from bovine cortical Bone(bBMP) by Urist method. The Bone Allograft chips were mixed with bovine Bone morphogenetic protein and red Bone marrow was implanted into the necrotic area of the femoral head after core decompression. Then, partial deminerallized Allograft fibula segments were settled in the core decompression holes to support the necrotic area to prevent from being collapsed in 64 adolescent patients (78 hips). Results: Preoperatively, pain, joint function, and CT scanning was evaluated in deferent time intervals. 55 cases(67 hips)were followed up form 3 months to 6 years(mean 44 months). 28 case(36 hips) in Ficat Ⅰ, Ⅱ were followed up over 3 years, of whom there were no obvious pain and dysfunction 18 cases (22 hips), high density new Bone was shown in core decompression area in CT scanning, and no evidence of progressing necrosis. There is no progressing in the symptoms in 4 cases(6 hips)in Ficat Ⅰ, Ⅱ, but the lesion progressed. In 6 cases (8 hips) in Ficat Ⅲ, there no obvious pain and dysfunction in 2 cases, but 4 cases undergone total hip replacement because of persistent pain and progressing lesion. Conclusion: The partial dematerialized Allograft fibula can provide direct mechanical support to prevent the necrotic femoral head from progressing and collapse, red Bone marrow and Bone morphogenetic protein promote new Bone formation. The method can be used as an alternative for the treatment of osteonecrosis of femoral head at stage Ⅰ, Ⅱ.
-
Treatment of avascular necrosis of femoral head by implanting a composite of autogenous Bone marrow and noncelluar tissue Engineered Bone Allograft with BMP
Chinese Journal of Orthopaedics, 2005Co-Authors: Yao Jian-huaAbstract:Objective To investigate the effect of treatment of avascular necrosis of femoral head in adolescence by implanting a composite of autogenous Bone marrow, Bone morphogenetic protein(BMP), and noncelluar tissue Engineered Bone Allograft. Methods The BMP was partially purified from bovine cortical Bone (bBMP) by Urist method. The Bone Allograft chips were mixed with bBMP and Bone marrow. The composite was implanted into the necrotic area of the femoral head after core decompression, then partial deminerallized Allograft fibula segments were inserted in the core decompression holes to support the necrotic area in preventing the collapse in 64 adolescent patients (78 hips). Results 55 cases (67 hips) were followed up for 3 months to 6 years(mean 44 months). 28 case(36 hips) in FicatⅠ,Ⅱ were followed up over 3 years, of whom there were no obvious pain and dysfunction in 18 cases(22 hips), high density new Bone was shown in core decompression area in CT scanning, and no evidence of progressive necrosis. There was no worsening of the symptoms in 4 cases(6 hips) in Ficat Ⅰand Ⅱ, but the lesion progressed. In 6 cases (8 hips) in Ficat Ⅲ, there were no obvious pain and dysfunction in 2 cases, but 4 cases underwent total hip replacement because of persistent pain and progressive lesion. Conclusion The partial demineralized Allograft fibula can provide direct mechanical support to prevent the necrotic femoral head from progress and collapse, autogenous Bone marrow and BMP is able to promote new Bone formation. The method can be used as an alternative for the treatment of osteonecrosis of femoral head at stage Ⅰ,Ⅱ.
Christopher A. Smith - One of the best experts on this subject based on the ideXlab platform.
-
Production of a safer, osteogenic, tissue Engineered Bone Allograft
2015Co-Authors: Christopher A. SmithAbstract:The use of Allograft Bone is effective in the treatment of large Bone loss following tumour removal or surgery. However, it is not osteogenic due to a lack of viable osteogenic cells and the remaining marrow material is potentially harmful to the recipient. Sterilisation techniques, such as gamma irradiation, are routinely used to improve the safety of these grafts; however this fails to remove the immunogenic material and may diminish the Bones innate properties. Thus, wash techniques are being developed to remove the deleterious marrow, whilst retaining the native properties of the Bone so that through tissue engineering, pre-osteogenic cells may be added to aid osseointegration. To this end, this study utilised a novel wash process (developed by the National Health Service Blood and Transplant Tissue services (NHSBT)) on whole human femoral heads, to assess the resulting material?s suitability as a biological scaffold for Bone tissue engineering (BTE). Following the wash process, marrow removal efficiency was analysed by biochemical testing and histological assessment, and biocompatibility of fresh-frozen and washed human Bone was assessed using extract cytotoxicity assays with BM-MSCs. The results showed a marrow removal efficiency of 99.5%, leaving a material with only 16.7 ng DNA/100mg of dry material, and which histologically displayed minimal cellular content demonstrating that this was an efficient wash process producing an acellular biological scaffold material (
-
production of a safer osteogenic tissue Engineered Bone Allograft
[Thesis]. Manchester UK: The University of Manchester; 2015., 2015Co-Authors: Christopher A. SmithAbstract:The use of Allograft Bone is effective in the treatment of large Bone loss following tumour removal or surgery. However, it is not osteogenic due to a lack of viable osteogenic cells and the remaining marrow material is potentially harmful to the recipient. Sterilisation techniques, such as gamma irradiation, are routinely used to improve the safety of these grafts; however this fails to remove the immunogenic material and may diminish the Bones innate properties. Thus, wash techniques are being developed to remove the deleterious marrow, whilst retaining the native properties of the Bone so that through tissue engineering, pre-osteogenic cells may be added to aid osseointegration. To this end, this study utilised a novel wash process (developed by the National Health Service Blood and Transplant Tissue services (NHSBT)) on whole human femoral heads, to assess the resulting material?s suitability as a biological scaffold for Bone tissue engineering (BTE). Following the wash process, marrow removal efficiency was analysed by biochemical testing and histological assessment, and biocompatibility of fresh-frozen and washed human Bone was assessed using extract cytotoxicity assays with BM-MSCs. The results showed a marrow removal efficiency of 99.5%, leaving a material with only 16.7 ng DNA/100mg of dry material, and which histologically displayed minimal cellular content demonstrating that this was an efficient wash process producing an acellular biological scaffold material (<50ng DNA/100mg Bone). Extract cytotoxicity testing indicated the material was biocompatible. Uniaxial compression to failure was performed on 1cm3 cubes using Bone samples from mirrored location of bilaterally halved femoral heads, with one half washed, whilst the other was fresh-frozen. A random orientated ?clinical? model was also utilised, with samples processed as fresh-frozen, washed and irradiated for comparative assessment. There was no significant change in the mechanical strength of the washed material compared to fresh-frozen samples or between sterilisation types, suggesting the washed Bone was mechanically comparable to existing Bone Allograft stock. BM-MSCs from both young (?50 years) and old donors (?70 years) were seeded on washed Bone cubes from young and old donors, and cultured in standard or osteogenic media. Samples were analysed at 0, 14 and 28 day timepoints for cell viability, osteogenic gene expression, alkaline phosphatase activity and histological analysis. Results indicated significant fold increases in cell metabolism at day 14 and 28, in both medium types compared to day 0 (p?0.001). QRT-PCR data showed increased expression of osteogenic markers RUNX2 (p?0.001), osteopontin (p?0.001) and osteocalcin (p?0.001) in both standard and osteogenic media with significantly higher RUNX2 and osteocalcin in osteogenic medium samples at day 28. Expression of osteogenic genes was significantly higher in young donor cells seeded on the washed Bone compared to old donor cells, as was expression in BM-MSCs cultured on old donor Bone compared to young Bone. This implies that the washed Bone was able to induce osteogenic differentiation in BM-MSCs, that young donor cells were better able to differentiate than old, and that old donor Bone was better able to induce osteogenic activity. Additionally, patient-matched BM-MSCs and ASCs, and BM-MSCs and BM-MNCs were seeded onto washed Bone cubes and cultured for 28 days in standard or osteogenic media, with gene expression and metabolic activity assessed. The washed Bone was able to induce osteogenic differentiation of ASCs. Moreover, BM-MNCs when cultured on washed Bone also expressed osteogenic genes, indicative of osteogenic differentiation. These results indicate the efficacy of a novel wash process in producing a biological acellular scaffold suitable for Bone tissue engineering. Interestingly, data also suggests that the age of the cell donor and Bone donor may effect osteogenic differentiation of seeded cells which has significant implications clinically.
Chang Hong-xing - One of the best experts on this subject based on the ideXlab platform.
-
Clinical Study for Repair of Bone Defect in Arthroplasty Surgery by Implanting a Composite of Tissue Engineered Bone Allograft
The Orthopedic Journal of China, 2003Co-Authors: Chang Hong-xingAbstract:Objective: To investigate the effect for repair of Bone defect in arthroplasty surgery by implanting a composite of tissue Engineered Bone Allograft. Methods:The Bone Allograft chips combined with Bone morphogenetic protein and Bone marrow cells were implanted into the area of Bone defect in 15 patients underwent arthroplasty surgery. Results: All the patients were followed up for 10 months to 5 years (mean 40 months). There were no Bone absorption or loosening surrounding the prosthesis. New Bone formation was more rapid and the clinical results were satisfactory. Conclusion: The method can promote new Bone formation and being used as an alternative for repair of Bone defect in arthroplasty surgery.